|
INTERMEDIX HOLDINGS INC. AND SUBSIDIARIES
<br />Consolidated Statements of Cash Flows
<br />(In thousands)
<br />Cash flows from operating activities:
<br />Net loss
<br />Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
<br />Depreciation and amortization of property, equipment, and computer software
<br />Amortization of intangible assets
<br />Amortization of debt issuance costs
<br />Write -off of unamortized debt issuance costs on early extinguishment of debt
<br />Stock -based compensation expense
<br />Deferred income taxes
<br />Benefit from income tax deduction in excess of recognized compensation
<br />Bad debt expense
<br />Straight -line rent accrual
<br />Other noncash items
<br />Changes in operating assets and liabilities, net of acquisitions:
<br />Accounts and notes receivable
<br />Income taxes receivable
<br />Prepaid expenses and other current assets
<br />Accounts payable and accrued expenses
<br />Accrued interest expense
<br />Accrued payroll and related benefits
<br />Deferred revenue
<br />Collections payable to clients
<br />Other assets /liabilities
<br />Net cash (used in) provided by operating activities
<br />Cash flows from investing activities:
<br />Cash paid to acquire Predecessor Company, net of cash acquired
<br />Deposits
<br />Capital expenditures
<br />Expenditures for computer software and developed technology
<br />Cost of business acquisitions
<br />Investment activities
<br />Net cash used in investing activities
<br />Cash flows from financing activities:
<br />Borrowings under revolving credit facility
<br />Borrowings under senior term loans
<br />Borrowings under subordinated debt facility
<br />Repayments under revolving credit facility
<br />Repayment of senior term loans
<br />Repayment of capital lease obligations
<br />Repayment of related party debt
<br />Proceeds from issuance of common stock in Successor Company
<br />Benefit from income tax deductions in excess of recognized compensation
<br />Payment of debt issuance costs
<br />Net cash provided by financing activities
<br />Net increase (decrease) in cash and cash equivalents
<br />Cash and cash equivalents, beginning of period
<br />Cash and cash equivalents, end of period
<br />Supplemental disclosures of cash flow information:
<br />Cash paid (received) during the year for:
<br />Interest
<br />Income taxes
<br />See accompanying notes to consolidated financial statements.
<br />Period from
<br />Period from
<br />August 23, to
<br />January 1, to
<br />December 31,
<br />August 22,
<br />2010
<br />2010
<br />(Successor)
<br />(Predecessor)
<br />6 (14,374)
<br />(19,955)
<br />2,147
<br />2,571
<br />9,571
<br />8,523
<br />455
<br />362
<br />—
<br />1,702
<br />816
<br />17,841
<br />(8,363)
<br />1,068
<br />—
<br />(3,221)
<br />853
<br />(235)
<br />44
<br />(20)
<br />(301)
<br />111
<br />(5,460)
<br />613
<br />957
<br />(6,316)
<br />50
<br />(3,765)
<br />(815)
<br />8,701
<br />665
<br />3,278
<br />1,330
<br />3,800
<br />1,902
<br />153
<br />6,702
<br />(6,077)
<br />65
<br />249
<br />(3,756)
<br />9,383
<br />(533,271)
<br />—
<br />10
<br />33
<br />(979)
<br />(1,247)
<br />(1,607)
<br />(1,801)
<br />—
<br />(53,707)
<br />(250)
<br />—
<br />(56,722)
<br />(536,097)
<br />16,500
<br />8,500
<br />195,000
<br />30,000
<br />85,000
<br />—
<br />(2,000)
<br />(8,500)
<br />(488)
<br />(313)
<br />(78)
<br />(151)
<br />—
<br />(655)
<br />273,924
<br />-
<br />-
<br />3,221
<br />(8,209)
<br />(1,101)
<br />559,649
<br />31,001
<br />19,796
<br />(16,338)
<br />—
<br />35,096
<br />$ 19,796
<br />18,758
<br />$ 9,442
<br />4,584
<br />(929)
<br />3,633
<br />
|